Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc.

VNDANYSE / NASDAQHealthcareSmall cap

$3.45-$0.22 (-6.0%)

Last close · Data as of Nov 20, 2026

Market cap
$375.8M
Revenue
$216.1M
Net margin
-102.0%
ROCE
-46.2%

-28.7% over the last year

Vanda Pharmaceuticals Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-17.3%
3M
-35.9%
6M
-44.2%
1Y
-28.7%
5Y
-79.7%

52-week range

Day change -$0.22 (-6.0%) from $3.67 to $3.45 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in VNDA, bought on each weekday since 2021.

News & filings

What Vanda Pharmaceuticals filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 220 million US dollars in fiscal 2025.

Strengths (1)

  • Cash on the balance sheet equals 70% of the company's market value.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.

Read moreShow less

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia and major depressive disorder; HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24; PONVORY (ponesimod) to treat psoriasis and ulcerative colitis; and NEREUSTM (tradipitant) for prevention of vomiting induced by GLP-1 receptor agonists, as well as treatment of gastroparesis and atopic dermatitis. In addition, the company's products include Imsidolimab, an IL-36R antagonist to treat generalized pustular psoriasis; VTR-297, for the treatment of hematologic malignancies and onychomycosis, and several oncology indications; and VQW-765, small molecule alpha-7 nicotinic acetylcholine receptor partial agonist for the treatment of social/performance anxiety and psychiatric disorders. Further, it develops cystic fibrosis transmembrane conductance regulator activators and inhibitors; and antisense oligonucleotide molecules. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Sector
Healthcare
Shares outstanding
59.1M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$375.8M
P/B
1.1x
EV / Sales
0.6x
P/S
1.7x
52-week high
$9.56
52-week low
$3.45

Profitability

Operating margin
-70.0%
Net margin
-102.0%
EBITDA margin
-64.4%
ROE
-67.4%
ROCE
-46.2%
ROIC
-46.8%
ROA
-45.1%
Asset turnover
0.44

Growth

Revenue
$216.1M
Revenue growth, 1Y
8.7%
Revenue CAGR, 3Y
-5.3%
Net profit growth, 1Y
1066.5%
Free cash flow
-$110.4M

Solvency

Current ratio
2.39
Debt / Equity
0.04
Debt / Assets
0.03
CFO / Net profit
0.50
Cash / Market cap
70.2%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$216.1M
Cost of revenue$13.0M
Gross profit$203.1M
Operating expenses$354.2M
Research and development$109.3M
Selling, general and administrative$237.9M
Operating income-$151.2M
Interest and other$12.5M
Pretax income-$138.7M
Tax and other$81.8M
Net income-$220.5M

Revenue and net profit

Revenue grew 8.7% in FY2025; net profit is the dashed line.

Vanda Pharmaceuticals Inc. revenue and net profit by fiscal year
Vanda Pharmaceuticals Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$254.4M$6.3M
FY2023$192.6M$2.5M
FY2024$198.8M-$18.9M
FY2025$216.1M-$220.5M

Cash flows

FY2025: -$109.4M from operations, -$110.4M free after investment (dashed).

Vanda Pharmaceuticals Inc. operating and free cash flow by fiscal year
Vanda Pharmaceuticals Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$32.0M$31.3M
FY2023$12.8M$12.4M
FY2024-$15.8M-$16.2M
FY2025-$109.4M-$110.4M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$216.1M+8.7%1Y
EBITDA
-$139.3M
Net profit
-$220.5M
Cash from operations
-$109.4M
Free cash flow
-$110.4M
Revenue CAGR, 3Y
-5.3%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$216.1M-$139.3M-$220.5M-$110.4M-67.4%+8.7%+1066.5%

Monthly returns

Month-by-month returns of VNDA across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$488.9M
Liabilities$161.8M
Equity$327.2M
Paid-in capital$721.3M
Retained earnings-$394.8M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; VNDA highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Vanda Pharmaceuticals Inc. (this company)0.6x

Not shown (no positive earnings and no EV / Sales): Compass Therapeutics, Inc., Benitec Biopharma Inc., Lexeo Therapeutics, Inc., Perspective Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Vanda Pharmaceuticals Inc.VNDAthis company$375.8M—1.1x-67.4%—
OmniAb, Inc.OABI$385.6M-6.0x1.4x-24.3%-8.1x
Compass Therapeutics, Inc.CMPX$383.6M-5.8x1.9x-33.8%-5.1x
Benitec Biopharma Inc.BNTC$379.6M-10.0x3.9x-39.0%-6.8x
Viemed Healthcare, Inc.VMD$377.2M25.3x2.7x10.6%7.4x
CapsoVision, Inc.CV$376.7M-14.9x28.4x-190.9%-14.7x
Lexeo Therapeutics, Inc.LXEO$375.3M-3.8x1.5x-40.5%-3.3x
Delcath Systems, Inc.DCTH$372.5M138.0x3.3x2.4%327.0x
Perspective Therapeutics, Inc.CATX$370.7M-3.6x1.8x-49.8%-3.4x
Peer median—-4.8x2.3x-36.4%-4.2x

Year-to-date ROI

VNDA since 1 January, against earlier years.

Historical volatility

VNDA's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Vanda Pharmaceuticals Inc. operating margin by fiscal year
Vanda Pharmaceuticals Inc. operating margin by fiscal year
DateOperating margin
FY20222.5%
FY2023-7.2%
FY2024-20.5%
FY2025-70.0%
LineFY2025
Cost of revenueCost Of Revenue$13.0M
Gross profitGross Profit$203.1M
Operating expensesOperating Expense$354.2M
Research and developmentResearch And Development$109.3M
Selling, general and administrativeSelling General And Administration$237.9M
Depreciation and amortisationDepreciation And Amortization In Income Statement$7.0M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$7.0M
Amortization$7.0M
Amortisation of intangiblesAmortization Of Intangibles Income Statement$7.0M
Total expensesTotal Expenses$367.3M
Pretax incomePretax Income-$138.7M

Learn while you research

Academy chapters picked for Vanda Pharmaceuticals Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →